Problem Definition
GeneCure Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. After 11 years of R&D and $840 million in cumulative investment, the company has received FDA approval for Zelvara — a one-time gene therapy for Meyerson Syndrome, a rare autosomal recessive disorder that causes progressive neuromuscular degeneration. Zelvara is the first gene therapy approved for this condition.
In Phase III clinical trials, Zelvara demonstrated an 89% durable response rate at 4-year follow-up, compared to 40% symptom control with the current standard of care — Celaris Therapeutics' enzyme replacement therapy Onzurel, which costs $180,000 per year and must be administered for life. Zelvara is a single intravenous infusion with a manufacturing cost of $85,000 per dose.
The GeneCure board is meeting next week to finalize the US launch price. Internal analyses have produced a range from $500,000 (a cost-plus model covering manufacturing, administration, and post-treatment monitoring) to $2.1 million (a value-based model pegged to lifetime standard-of-care costs). Congressional hearings on gene therapy pricing are expected in Q3. A Phase III competitor, NovaStar Bio, is 18-24 months behind. The board has hired your firm to recommend a launch price and market access strategy for Zelvara. What price should GeneCure set, and how should they structure payer agreements to maximize both revenue and patient access?
Additional InformationAsk for more dataHide data
(Share only when prompted by the candidate)
- Meyerson Syndrome prevalence is approximately 12,000 patients in the US, but only 4,200 are clinically diagnosed; of those, 2,800 have insurance with a realistic coverage pathway for gene therapy
- Average remaining treatment duration for diagnosed patients is 12 years
- New diagnoses enter the pool at approximately 200 patients per year
- GeneCure has $180M in cash reserves and needs to reach profitability within 36 months or raise additional capital at dilutive terms
- 68% of commercial payers have indicated willingness to negotiate outcomes-based contracts for gene therapies priced under $1.5M
- Medicare covers approximately 30% of diagnosed patients; CMS has signaled openness to installment-based payment models
- Manufacturing capacity is currently 600 doses per year, expandable to 1,200 with a $45M facility investment
- The FDA has granted GeneCure 7 years of orphan drug exclusivity
- GeneCure has no other products in its commercial portfolio; Zelvara is its only revenue source
- Three patient advocacy groups have publicly stated that any price above $1M would be "unconscionable"
- EU and Japan launches are planned for 18 months after the US launch; reference pricing is a concern
Question 1Structuring
"How would you structure your approach to recommending a launch price for Zelvara?"
Hint · Structuring
Build 3–4 branches that are specific to this client and question, not a generic framework. Check they don't overlap and together cover the problem.
Additional Information for Question 1Ask for more dataHide data
- Share the problem definition as stated above
- If candidate asks about portfolio: GeneCure has no other products; Zelvara is its only revenue source
- If candidate asks about patient advocacy: Three advocacy groups have publicly stated any price above $1M would be "unconscionable"
- If candidate asks about international: EU and Japan launches planned 18 months after the US; reference pricing is a concern
- If candidate asks about QALY benchmarks: The US does not have a formal QALY threshold, but $150K per QALY is a commonly cited willingness-to-pay benchmark; Zelvara generates approximately 1.8 incremental QALYs per patient over standard of care
- If candidate asks about comparable launches: Novartis's Zolgensma launched at $2.125M for spinal muscular atrophy; Bluebird Bio's Zynteglo launched at $2.8M for beta-thalassemia but faced severe payer resistance and was withdrawn from the European market
Try it first, then checkShow model answerHide model answer
A strong structure addresses four interconnected areas:
-
Value Architecture — Quantify the clinical and economic value Zelvara creates relative to standard of care. Calculate lifetime cost avoidance, QALY gains, and indirect savings. Establish a value-based ceiling and floor.
-
Market Reality — Size the true addressable market using the patient funnel (not headline prevalence). Model revenue trajectories at multiple price points, factoring the shrinking patient pool, new diagnoses, and the competitor timeline.
-
Access Design — Determine which payer agreement structures (outcomes-based rebates, installment payments, indication-based pricing) maximize coverage probability. Segment payers by type (commercial, Medicare, Medicaid) with tailored approaches.
-
Strategic Constraints — Map the binding constraints: 36-month cash runway, 600-dose/year manufacturing capacity, 7-year orphan exclusivity window, Congressional scrutiny timeline, and EU reference pricing implications.
What the interviewer is looking forShow guidanceHide guidance
Good (Level 1 — Surface): Candidate identifies the key pricing dimensions — cost-based, value-based, and competitive benchmarking. Mentions payer dynamics and patient access. Applies a recognizable pricing framework with relevant categories.
Strong (Level 2 — Implication): Candidate identifies the core tension: the value-based ceiling ($2.1M) is defensible on health economics but creates political and access risk that limits volume. Recognizes that a one-time gene therapy creates a fundamentally different P&L profile from chronic treatments — revenue is front-loaded and decays as the addressable pool shrinks. Considers time pressure: orphan exclusivity, competitor timeline, and cash runway create a "pricing clock."
Excellent (Level 3 — Actionable): Candidate frames the problem as simultaneous optimization across three constraints: (1) price high enough to recoup R&D and fund operations within the 36-month cash runway, (2) price low enough to secure payer coverage and volume given the 600-dose manufacturing cap, (3) price defensible enough to survive Congressional scrutiny and protect EU reference pricing. Notes that manufacturing capacity acts as a natural volume ceiling in Year 1, which decouples the pricing decision from short-term volume anxiety. Identifies outcomes-based contracts as both a payer negotiation tool and a political shield.
Question 2Numeracy
"Using Exhibit 1, calculate the minimum price per dose that allows GeneCure to break even on its total investment within the first three years of launch."
Hint · Numeracy
Write the formula before you plug in numbers, keep units and zeros explicit, and sanity-check the order of magnitude at the end.
Additional Information for Question 2Ask for more dataHide data
Share Exhibit 1 (Patient Population Funnel) and provide the following when asked:
- R&D investment to recoup: $840M
- Projected treatment volumes: Year 1: 280 patients, Year 2: 420 patients, Year 3: 500 patients
- Manufacturing cost per dose: $85,000
- Annual SG&A and market access costs: $120M per year
- Ignore discounting for this calculation
Exhibit 1Patient Population Funnel — Meyerson Syndrome (US)
| Funnel Stage | Patients | % of Previous Stage | Notes |
|---|---|---|---|
| Estimated total prevalence | 12,000 | — | Based on genetic screening studies |
| Clinically diagnosed | 4,200 | 35% | Requires specialized genetic testing |
| Eligible for gene therapy | 3,600 | 86% | Excludes age >65 and severe comorbidities |
| Insured with coverage pathway | 2,800 | 78% | Commercial + Medicare; excludes uninsured and Medicaid gaps |
| New diagnoses entering pool per year | 200 | — | Incremental annual additions |
Source: GeneCure Therapeutics case file
Try it first, then checkShow model answerHide model answer
Calculation
Step 1: Confirm addressable market from Exhibit 1
| Funnel Stage | Patients |
|---|---|
| Total prevalence | 12,000 |
| Clinically diagnosed | 4,200 |
| Eligible for gene therapy | 3,600 |
| Insured with coverage pathway | 2,800 |
Addressable market = 2,800 patients
Step 2: Total patients treated in Years 1-3
| Year | Patients Treated |
|---|---|
| Year 1 | 280 |
| Year 2 | 420 |
| Year 3 | 500 |
| Total | 1,200 |
Step 3: Total costs over 3 years
| Cost Component | Calculation | Total |
|---|---|---|
| R&D recoupment | Sunk investment | $840M |
| Manufacturing | 1,200 doses x $85K | $102M |
| SG&A and market access | $120M x 3 years | $360M |
| Total | $1,302M |
Step 4: Break-even price per dose
Break-even price = $1,302M / 1,200 patients = $1,085,000 per dose (approximately $1.1M)
Step 5: Sanity checks
| Check | Result |
|---|---|
| Above manufacturing cost ($85K)? | Yes — 12.8x manufacturing margin |
| Below value-based ceiling ($2.1M)? | Yes — 52% of the ceiling |
| Under $1.5M payer willingness threshold? | Yes — within the 68% willing-to-negotiate range |
| Manufacturing feasible (Year 1)? | 280 < 600 capacity — feasible |
| Manufacturing feasible (Year 2-3)? | 420 and 500 exceed 600 — expansion required |
The minimum break-even price is approximately $1.1M per dose. A candidate who used 12,000 as the base would arrive at approximately $108K — an obviously unrealistic gene therapy price that should prompt self-correction.
What the interviewer is looking forShow guidanceHide guidance
Candidates must first recognize from Exhibit 1 that the addressable market is 2,800 patients, not 12,000. A candidate who begins calculating with the headline prevalence figure should be redirected: "Take another look at the funnel — how many patients can GeneCure actually reach?"
Follow-Up Probes
- "What happens to the break-even price if NovaStar launches in 2027 and captures 40% of remaining untreated patients?" (Answer: Fewer patients in Years 4-5 accelerates the need to recoup in Years 1-3, reinforcing the $1.1M floor or pushing it higher.)
- "GeneCure's manufacturing capacity is 600 doses in Year 1, but the plan calls for 280. Is that a problem?" (Answer: No — it provides strategic optionality. GeneCure can prioritize high-value payer contracts and the most favorable patient demographics first. The spare capacity is insurance against faster-than-expected uptake.)
- "What if the candidate forgot to subtract manufacturing and SG&A?" (They would arrive at $840M / 1,200 = $700K — below manufacturing margin requirements and ignoring operating costs. Redirect: "Does that price cover the costs of actually making and selling the drug?")
Question 3Judgement & Insights
"Review Exhibits 2 and 3. What pricing strategy would you recommend, and what risks should the board be aware of?"
Hint · Judgement & Insights
Read the exhibit title, axes and units first. Lead with the ‘so what’, then back it with one or two numbers.
Additional Information for Question 3Ask for more dataHide data
Share Exhibits 2 and 3. Allow the candidate 60 seconds to study them before responding.
- If candidate asks about discount rates: Payers typically use 3-5% for health economic evaluations; pharma companies often model at 8-10% to reflect cost of capital
- If candidate asks about NovaStar's trial: NS-4120 is a CRISPR-based gene editing approach with preliminary Phase II efficacy of 82% (vs. Zelvara's 89%); however, CRISPR therapies carry different long-term safety perception risks
- If candidate asks about payer contracting timelines: Large commercial payers typically take 6-12 months to complete formulary review and negotiate contracts for novel gene therapies
Exhibit 2Lifetime Economic Comparison per Patient (Undiscounted)
| Component | Standard of Care (Onzurel) | Gene Therapy (Zelvara) |
|---|---|---|
| Annual drug/treatment cost | $180,000 | One-time infusion |
| Average remaining treatment years | 12 | — |
| Lifetime drug cost | $2,160,000 | Launch price (TBD) |
| Annual monitoring and administration | $15,000 | $8,000 (Years 1-3 only) |
| Lifetime monitoring cost | $180,000 | $24,000 |
| Disease-related hospitalizations per year | $22,000 | Reduced by 89% |
| Lifetime hospitalization cost | $264,000 | $29,000 |
| Total lifetime direct medical cost | $2,604,000 | Launch price + $53,000 |
| Efficacy rate | 40% symptom control | 89% durable response |
Note: All figures are undiscounted and assume continuous treatment for the full remaining duration.
Source: GeneCure Therapeutics case file
Exhibit 3Competitive Pipeline — Meyerson Syndrome Therapies
| Company | Therapy | Mechanism | Phase | Expected Approval | Est. Price | Notes |
|---|---|---|---|---|---|---|
| Celaris Therapeutics | Onzurel | Enzyme replacement (weekly infusion) | Approved | On market | $180K/year | Current standard of care |
| NovaStar Bio | NS-4120 | Gene editing (CRISPR) | Phase III | 2027 | $900K-1.1M | Enrolling 800-patient pivotal trial |
| Helix Genomics | HGT-301 | Gene replacement | Phase II | 2029 | TBD | Smaller cohort (n=120) |
| Renovia Health | RH-Mey | Antisense oligonucleotide (daily oral) | Phase II | 2028 | $95K/year | Chronic therapy; not curative |
| BioVance | BV-2200 | Modified gene therapy | Phase I | 2031+ | TBD | Early safety data only |
Source: GeneCure Therapeutics case file
Try it first, then checkShow model answerHide model answer
The pricing strategy must account for three layers of insight from the exhibits:
Layer 1 — Adjust the value ceiling (Exhibit 2): The headline $2.6M lifetime SoC cost is undiscounted. Applying a 5% discount rate to $180K/year over 12 years yields a present value of approximately $1.6M. Adding discounted monitoring ($133K) and hospitalization ($185K) brings the adjusted ceiling to roughly $1.9M. This — not $2.6M — is the defensible value-based anchor.
Layer 2 — Prioritize the real threat (Exhibit 3): NovaStar's Phase III trial is the only near-term constraint. Their estimated $900K-1.1M price at 82% efficacy (lower than Zelvara's 89%) means GeneCure can price above NovaStar if it can demonstrate superior outcomes and lock in payer relationships first. Renovia's oral therapy at $95K/year is relevant only for the gene-therapy-averse segment. Helix and BioVance are too early to affect launch strategy.
Layer 3 — Design the temporal strategy: Launch at $1.2M with outcomes-based contracts that include 3-year volume commitments from payers. This creates contractual switching costs: even when NovaStar arrives at $900K-1.1M, payers already committed to GeneCure's outcomes-based framework face administrative and financial costs to switch. The 600-dose manufacturing cap in Year 1 actually helps — constrained supply at a moderate price signals value, not desperation.
Key risks to flag for the board:
- Regulatory risk: If CMS sets a national coverage determination with a lower reference price, commercial payers will follow
- Political risk: Congressional hearings could trigger executive action on drug pricing before GeneCure reaches profitability
- Efficacy risk: The 89% rate is based on 4-year data; if durability declines at Year 5-7, outcomes-based contracts become costly rebate obligations
- Pool exhaustion risk: With only 2,800 addressable patients and 200 new diagnoses per year, the addressable pool is largely treated by Year 5-6, creating a revenue cliff
Good: Identifies NovaStar as the primary competitive threat and notes the value-based ceiling from Exhibit 2.
Strong: Catches the discounting trap in Exhibit 2 and adjusts the ceiling downward. Recognizes the competitive timeline creates urgency for payer contract lock-in before 2027.
Excellent: Synthesizes across both exhibits to argue that pricing is a temporal strategy, not a static number. Recommends a launch price enabling rapid payer adoption (under $1.5M), paired with outcomes-based contracts creating switching costs that pre-empt NovaStar. Notes that the 600-dose manufacturing cap in Year 1 means GeneCure cannot serve full demand regardless, which provides cover for not racing to the floor.
What the interviewer is looking forShow guidanceHide guidance
Key insights the candidate should surface:
-
Exhibit 2 trap — undiscounted figures: The lifetime SoC cost of $2,604,000 makes a $1.2M gene therapy look like a dramatic bargain. But these are undiscounted figures spread over 12 years. At a 5% discount rate, the present value of $180K/year for 12 years drops to approximately $1.6M. At 8%, it falls to approximately $1.35M. Candidates who cite the $2.6M headline without adjusting for time value are overstating the value proposition.
-
Exhibit 3 trap — unequal competitive threats: NovaStar Bio (NS-4120) is in Phase III with an estimated 2027 approval at $900K-1.1M. This is a real and imminent pricing ceiling. However, Helix Genomics (Phase II, 2029) and BioVance (Phase I, 2031+) are far enough out that they do not constrain near-term decisions. Renovia Health's antisense oligonucleotide (Phase II, 2028) is a chronic therapy at $95K/year — it competes for patients who refuse gene therapy, not for gene therapy patients. Candidates who treat all five pipeline entries as equal threats are misreading the exhibit.
-
The intersection: GeneCure needs to price high enough to recoup R&D before NovaStar arrives, but low enough to lock in payer contracts with switching costs. A price in the $1.1-1.4M range with outcomes-based agreements creates durable payer relationships that are difficult for NovaStar to displace — even at a lower sticker price.
Question 4Synthesis
"The GeneCure board meets in one week. Please give your final recommendation in two minutes."
Hint · Synthesis
Answer first: the recommendation, two or three reasons with numbers, then risks and next steps.
What the interviewer is looking forShow guidanceHide guidance
A strong recommendation integrates four elements:
-
A specific price with rationale: Launch Zelvara at $1.2M per dose. This is above the $1.1M break-even, below the $1.5M payer negotiation threshold, and positions as a 44% discount to lifetime standard-of-care costs (undiscounted). It provides margin for R&D recoupment while remaining defensible to Congress and payers.
-
A payer access strategy: Offer outcomes-based contracts with a 20% rebate if Zelvara fails to achieve durable response at 24-month follow-up. This reduces effective payer risk to $960K for non-responders, accelerates formulary inclusion, and serves as political cover. For Medicare patients (~30% of the diagnosed pool), propose installment payments of $400K per year over 3 years to distribute budget impact.
-
A volume and capacity plan: Treat 280 patients in Year 1 within the existing 600-dose capacity. Invest $45M to expand manufacturing to 1,200 doses ahead of Year 2 demand. Prioritize contracts with the top 20 treatment centers, which cover approximately 60% of diagnosed patients, before NovaStar's expected 2027 approval.
-
A risk mitigation plan: Establish a patient assistance fund ($15M/year) covering uninsured and underinsured patients. Proactively brief Congressional offices with health economics data showing Zelvara saves $960K per patient versus lifetime SoC. Set an international reference pricing strategy before EU launch to avoid anchoring European negotiations to the US list price.
What "excellent" sounds like: The candidate frames the recommendation not as "pick a number" but as "design a system" — the price, the contract structure, the volume ramp, and the political strategy are interdependent. The $1.2M price works only when paired with outcomes-based contracts (political defense), capacity expansion (volume capture), and pre-emptive payer lock-in (competitive moat against NovaStar).
Common Pitfalls in Synthesis
- Anchoring on $2.1M value-based price: Candidates who recommend prices above $1.5M without addressing the 68% payer threshold or Congressional risk are optimizing for unit economics while ignoring market access realities
- Ignoring the cash runway: GeneCure has 36 months to profitability. A recommendation that maximizes long-term NPV but leaves the company insolvent at month 30 is not actionable
- Treating pricing as a one-time decision: The best candidates recognize that the launch price can be adjusted — outcomes-based rebates, volume tiers, and international reference pricing all create mechanisms to modulate effective price over time without changing the headline number
- Forgetting the 11% non-responders: At 89% efficacy, roughly 1 in 9 patients will not respond. Outcomes-based contracts must account for this — a 20% rebate on non-responders is not generosity, it is pricing in the known failure rate
Contributed by CaseDrill practice community